Skip to main content
. 2022 Jun 5;14(6):1202. doi: 10.3390/pharmaceutics14061202

Figure 2.

Figure 2

Assessment of binding affinity of BS−LipoIRI. (A) Different concentrations of anti-EGFR/anti-FAP antibody for LipoIRI. (B) BxPC3/EGFR cellular binding affinity and (C) WS1/FAP cellular binding affinity. (Data are presented as mean ± SD, *: p < 0.01.)